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Table S1. Marine compounds evaluated in the current study, including 
molecular weight and molecular formula. 
Compound Molecular 
weight (Da) 
Molecular 
formula 
3-bromotyramine 216.08 C8H10BrNO 
4-hydroxybenzaldehyde 122.12 C7H6O2 
6-cyclohexamidemanzamine A 673.92 C43H55N5O2 
6-deoxy-manzamine X 564.76 C36H44N4O2 
6-nitroharmane 227.07 C12H9N3O2 
8-isopropyl-manzamine A 606.39 C39H50N4O2 
8-OH-manzamine 564.35 C36H44N4O2 
Aaptamine 228.25 C13H12N2O2 
Aplysinopsin 254.29 C14H14N4O 
Curcudiol 236.18 C15H24O2 
Cyanthiwigin C 288.47 C20H32O 
Elysia_910 909.50 Unknown 
Hawaiimycin B 344.20 C48H82O18 
Hawaiimycin C 960.57 C49H84O18 
Ilimaquinone 344.20 C21H28O4 
Indole-3-carboxaldehyde 145.16 C9H7NO 
Ircinal A 410.29 C26H38N2O2 
Ircinol A 412.60 C26H40N2O2 
Isoaaptamine 228.25 C13H12N2O2 
Kahalalide F 1476.93 C75H124N14O16 
Manzamine A 548.35 C22H24Br2N10O2 
Manzamine D 552.79 C36H48N4O 
Manzamine E 564.76 C36H48N4O 
Manzamine F 580.00 C36H44N4O3 
Sceptrin 620.29 C22H24Br2N10O2 
Theonellapeptilide 1d 1404.00 Unknown 
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Purity of compounds (1 - 6) by 1H NMR, LC-MS and MS/MS. 
 
 
                   Figure S1.  a) 1H NMR spectrum (400 MHz, pyridine-d5), b) LCMS and c) MS/MS of manzamine A (1). 
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  Figure S2. A) 1H NMR spectrum (400 MHz, pyridine-d5) b), LCMS and c) MS/MS of 8 hydroxymanzamine A (2). 
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Figure S3.  a) 1H NMR spectrum (400 MHz, Methanol-d4), b) LCMS and c) MS/MS of manzamine E (3). 
 
 
 
 
 
 Simithy, J., et al.; Slow-binding inhibition of MtSK by manzamines; Page {PAGE  } of 23 
 
 
 
 
Figure S4.  a) 1H NMR spectrum (400 MHz, Methanol-d4), b) LCMS and c) MS/MS of manzamine F (4). 
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Figure S5.  a) 1H NMR spectrum (400 MHz, Methanol-d4), b) LCMS and c) MS/MS of manzamine X (5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6.  a) 1H NMR spectrum (400 MHz, Methanol-d4+drops of Acetone), b) LCMS and c) LRMS of 6-
cyclohexamidomanzamine A (6). 
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Analyses of Rapid Reversible Inhibition: Equations and Data 
 
Shikimate kinase catalyzes a phosphoryl transfer from ATP to shikimate (SA) in order to form ADP 
and shikimate-3-phosphate (S3P). Consistent with a wealth of structural data including free MtSK and its 
complexes with substrates and/or substrate analogs, kinetic evaluation indicates that the enzyme follows a 
random-sequential substrate binding model.1 Stated another way, all indications are that the term “α” (see 
Fig. 2) is close to 1.1 To determine the possible participation of common rapid-reversible modes of inhibition 
(i.e., competitive vs uncompetitive vs pure noncompetitive vs mixed noncompetitive), we evaluated our 
kinetic data in the context of a cuboid model (see Fig. 2).2 Such a model allows that the inhibitor (I) is 
capable of binding the free enzyme (E), either ES binary complex (i.e, E-SA and E-ATP), and the ternary E-
SA-ATP complex. Using rapid-equilibrium assumptions, a rate equation can be derived to approximate 
MtSK kinetic behavior in the presence of such a rapid-reversible inhibitor (equation S1). Here, the influence  
 
𝑣𝑣𝑜𝑜 [E]T� = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐[SA][ATP]𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴𝐾𝐾𝑆𝑆𝐴𝐴 + 𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[SA] + 𝛼𝛼𝐾𝐾𝑆𝑆𝐴𝐴[ATP] + 𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴𝐾𝐾𝑆𝑆𝐴𝐴[I] 𝐾𝐾𝐼𝐼� + [SA][ATP] + 𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[SA][I] 𝛾𝛾𝐾𝐾𝐼𝐼� + 𝛼𝛼𝐾𝐾𝑆𝑆𝐴𝐴[ATP][I] 𝛽𝛽𝐾𝐾𝐼𝐼� + [SA][ATP][I] 𝛽𝛽𝛾𝛾𝐾𝐾𝐼𝐼�  
 
of ATP and inhibitor (I) on one another’s binding is accounted for by the term “β”, and the influence of 
shikimate (SA) and (I) on one another’s binding is accounted for by the term “γ”.  As such, four KI terms are 
anticipated, KI for I binding to the free enzyme, βKI to describe I binding to the E-ATP complex, γKI to 
describe I binding to the E-SA, and βγKI to describe I binding to the ternary complex. Of course, equation S1 
can be divided into two. Equation S2 applies when the concentration of ATP is held constant and SA is 
varied, and equation S3 applies when the concentration of SA is held constant and ATP is varied. Further,  
            𝑣𝑣𝑜𝑜[E]T = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐  [SA]α𝐾𝐾𝑆𝑆𝐴𝐴 �1 +  𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[ATP] + 𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[I][ATP]𝐾𝐾I +  [I]𝛽𝛽𝐾𝐾I� + [SA] �1 +  𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[ATP] + 𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[I][ATP]𝛾𝛾𝐾𝐾I + [I]𝛽𝛽𝛾𝛾𝐾𝐾I�        (𝐒𝐒𝐒𝐒) 
            𝑣𝑣𝑜𝑜[E]T = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐  [ATP]α𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴 �1 + 𝐾𝐾𝑆𝑆𝐴𝐴[SA] + 𝐾𝐾𝑆𝑆𝐴𝐴[I][SA]𝐾𝐾I + [I]𝛾𝛾𝐾𝐾I� + [ATP] �1 + 𝛼𝛼𝐾𝐾𝑆𝑆𝐴𝐴[SA] + 𝛼𝛼𝐾𝐾𝑆𝑆𝐴𝐴[I][SA]𝛽𝛽𝐾𝐾I + [I]𝛽𝛽𝛾𝛾𝐾𝐾I�                (𝐒𝐒𝐒𝐒) 
 
under circumstances where the concentration of the constant substrate is saturating (i.e., [ATP]>>KATP and 
αKATP or [SA]>>KSA and αKSA), then equations 2 and 3 can be approximated by equations S4 and S5, 
respectively.2  Each of these equations would support a mixed-inhibition model.  
             𝑣𝑣𝑜𝑜[E]T = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐  [SA]α𝐾𝐾𝑆𝑆𝐴𝐴 �1 + [I]𝛽𝛽𝐾𝐾I� + [SA] �1 +  [I]𝛽𝛽𝛾𝛾𝐾𝐾I�        (𝐒𝐒𝐒𝐒) 
            𝑣𝑣𝑜𝑜[E]T = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐  [ATP]α𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴 �1 +  [I]𝛾𝛾𝐾𝐾I� + [ATP] �1 + [I]𝛽𝛽𝛾𝛾𝐾𝐾I�      (𝐒𝐒𝐒𝐒) 
 
Using the Prism software mixed inhibition model, two inhibition parameters are returned, “α” and 
“KI”.  Translating to the two-substrate system of MtSK, “α” would correspond to γ and “KI” would 
correspond to βKI in experiments where ATP was held at constant and saturating concentrations. Likewise, 
“α” would correspond to β, and “KI” would correspond to γKI in experiments where SA was held at constant 
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and saturating concentrations. This approach for evaluating MtSK inhibition by manzamine A (1) is shown 
for experiments where SA was held constant and ATP varied (Fig. S7A) and for experiments where ATP 
was held constant and SA varied (Fig. S7D).  The same type of analysis for MtSK inhibition by 6-
cyclohexamidomanzamine A (6) is shown for constant SA (Fig. S8A) and constant ATP (Fig. S8D). 
 
 An alternative way to evaluate these kinetic data is to determine the effect of inhibitor on the 
apparent kcat of MtSK as well as the apparent kon (i.e., kcat /KM) with respect to each substrate. This involves 
fitting reach curve to determine its individual Michaelis-Menten parameters (kon or kcat/KM).  The individually 
fit rate curves for each concentration of manzamine A (1) can be found in Fig. S7B (constant shikimate; 
varied ATP) and Fig. S7E (constant ATP; varied shikimate). The same can be found for 
cyclohexamidomanzamine A (6) in Fig. S8B and S8E, respectively. From equation S2 (experiments carried 
out with constant concentrations of ATP), the apparent kon[SA] (i.e., kcat/KM with respect to SA) is given by 
equation S6, and the apparent kcat is given by equation S7. In a similar manner, 
 
            
�𝑘𝑘𝑜𝑜𝑜𝑜[𝑆𝑆𝐴𝐴]�𝑐𝑐𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐
𝛼𝛼𝐾𝐾𝑆𝑆𝐴𝐴 �1 + 𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[ATP] + 𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[I][ATP]𝐾𝐾𝐼𝐼 + [I]𝛽𝛽𝐾𝐾𝐼𝐼�         (𝐒𝐒𝐒𝐒) 
 
 (𝑺𝑺𝑺𝑺)    (𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐)𝑐𝑐𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐
�1 + 𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[ATP] + 𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴[I][ATP]𝛾𝛾𝐾𝐾𝐼𝐼 + [I]𝛽𝛽𝛾𝛾𝐾𝐾𝐼𝐼�           (S𝑺𝑺) 
 
when SA is held constant the apparent kon[ATP] (i.e., the apparent kcat/KM with respect to ATP) is given by 
equation S8, and the apparent kcat is given by equation S9.  Supposing that the fixed-concentration  
 
           
�𝑘𝑘𝑜𝑜𝑜𝑜[𝐴𝐴𝐴𝐴𝐴𝐴]�𝑐𝑐𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐
𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴 �1 + 𝐾𝐾𝑆𝑆𝐴𝐴[SA] + 𝐾𝐾𝑆𝑆𝐴𝐴[I][SA]𝐾𝐾𝐼𝐼 + [I]𝛾𝛾𝐾𝐾𝐼𝐼�      (𝐒𝐒𝐒𝐒) 
 (𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐)𝑐𝑐𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐
�1 + 𝛼𝛼𝐾𝐾𝑆𝑆𝐴𝐴[SA] + 𝛼𝛼𝐾𝐾𝑆𝑆𝐴𝐴[I][SA]𝛽𝛽𝐾𝐾𝐼𝐼 + [I]𝛽𝛽𝛾𝛾𝐾𝐾𝐼𝐼�             (S𝟗𝟗) 
 
substrate is at a saturating concentration, equations S6 – S9 simplify to three equations. When ATP is the 
fixed substrate, the effect of inhibitor on the apparent kcat/KM with respect to SA (i.e., kon(SA)) (equation S10) 
can be used to estimate βKI. When SA is the fixed substrate, the effect of inhibitor on the apparent kcat/KM 
with respect to ATP (i.e., kon(ATP)) (equation S11) can be used to estimate γKI.  
 
           
�𝑘𝑘𝑜𝑜𝑜𝑜[𝑆𝑆𝐴𝐴]�𝑐𝑐𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐
𝛼𝛼𝐾𝐾𝑆𝑆𝐴𝐴 �1 + [I]𝛽𝛽𝐾𝐾𝐼𝐼�         (𝐒𝐒𝐒𝐒𝐒𝐒) 
           
�𝑘𝑘𝑜𝑜𝑜𝑜[𝐴𝐴𝐴𝐴𝐴𝐴]�𝑐𝑐𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐
𝛼𝛼𝐾𝐾𝐴𝐴𝐴𝐴𝐴𝐴 �1 + [I]𝛾𝛾𝐾𝐾𝐼𝐼�      (𝐒𝐒𝐒𝐒𝐒𝐒) 
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Finally, βγKI can be determined when either ATP or SA is the fixed substrate at saturating concentration, 
because the effect of inhibitor on the apparent kcat (equation S12) is the same in either case. 
          (𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐)𝑐𝑐𝑎𝑎𝑎𝑎 = 𝑘𝑘𝑐𝑐𝑐𝑐𝑐𝑐
�1 + [I]𝛽𝛽𝛾𝛾𝐾𝐾𝐼𝐼�          (𝐒𝐒𝐒𝐒𝐒𝐒) 
The applications of equations S12 and S11 to evaluate inhibition of MtSK by 1 with fixed saturating 
SA and varied ATP are shown in Figs. S7C and S7D, respectively. The applications of equations S12 and 
S10 to evaluate inhibition of MtSK by 1 with fixed saturating ATP and varied SA are shown if Fig. S7G and 
S7H, respectively. Likewise, the applications of equations S12 and S11 to evaluate inhibition of MtSK by 6 
with fixed saturating SA and varied ATP are shown in Figs. S8C and S8D, respectively. The applications of 
equations S12 and S10 to evaluate inhibition of MtSK by 6 with fixed saturating ATP and varied SA are 
shown if Figs. S8G and S8H, respectively.  The analogous experiments for 6-hydroxymanzamine A (2), 
manzamine E (3), manzamine F (4), and 6-deoxymanzamine X (5) are presented in Figs. S9, S10, S11, and 
S12, respectively. In all replots, the error bars show the standard errors from the fit of the individual rate 
curves to equation 1. 
 
Given the observation of time-dependent inhibition with these compounds, it is important to 
ascertain the extent to which the analyses of the standard steady-state inhibition experiments (see above) may 
be distorted by the increase in inhibition over time. We used kinetic modeling to determine the expected 
impact of time-dependent inhibition on steady-state inhibition assays carried out as described. Our model 
was based on the inhibitor with the largest k5 and the largest k5/k6 ratio (i.e., 6), and therefore, the inhibitor 
likely to produce the greatest distortion in steady-state inhibition studies.  Whether the MtSK mechanism was 
represented as a simple single-substrate, single-product Michaelis-Menten enzyme, or more accurately as a 
random sequential bi-bi enzyme, the results were nearly identical; the largest impact of time-dependent 
inhibition was observed when the inhibitor was able to bind to all enzyme-substrate complexes and the slow 
isomerization step could occur from any initial enzyme inhibitor complex. Even under a model to maximize 
the effect, time-dependent inhibition was predicted to have very little impact on MtSK activity within the 30-
s time window of our steady-state enzyme assays (Fig. S13). 
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Figure S7. Non-linear least-squares analyses of rapid reversible inhibition by manzamine A (1). Data 
acquired varying [ATP] at fixed [SA] were either fit to a global mixed-noncompetitive mechanism of 
inhibition (A) or as individual Michaelis-Menten curves (B). Replots of (kcat)app and (kcat/KM)app obtained from 
panel B as a function of 1 are shown in (C) and (D), respectively. Data acquired varying [SA] at fixed [ATP] 
were either fit to a global mixed-noncompetitive mechanism of inhibition (E) or as individual Michaelis-
Menten curves (F). Replots of (kcat)app and (kcat/KM)app obtained from panel F as a function of 1 are shown in 
(G) and (H), respectively. Concentrations of 1 evaluated were 0 ( ), 25 (), 50 (), 100 (), 150 (), and 
200 () µM.  
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Figure S8. Non-linear least-squares analyses of rapid reversible inhibition by 6-cyclohexamido-
manzamine A (6). Data acquired varying [ATP] at fixed [SA] were either fit to a global mixed-
noncompetitive mechanism of inhibition (A) or as individual Michaelis-Menten curves (B). Replots of 
(kcat)app and (kcat/KM)app obtained from panel B as a function of 6 are shown in (C) and (D), respectively. Data 
acquired varying [SA] at fixed [ATP] were either fit to a global mixed-noncompetitive mechanism of 
inhibition (E) or as individual Michaelis-Menten curves (F). Replots of (kcat)app and (kcat/KM)app obtained from 
panel F as a function of 6 are shown in (G) and (H), respectively. Concentrations of 6 evaluated were 0 ( ), 
3.12 (), 6.25 (), 12.5 (), 25 (), and 50 () µM. 
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Figure S9. Non-linear least-squares analyses of rapid reversible inhibition by 8-hydroxymanzamine A 
(2). Data acquired varying [ATP] at fixed [SA] were either fit to a global mixed-noncompetitive mechanism 
of inhibition (A) or as individual Michaelis-Menten curves (B). Replots of (kcat)app and (kcat/KM)app obtained 
from panel B as a function of 2 are shown in (C) and (D), respectively. Data acquired varying [SA] at fixed 
[ATP] were either fit to a global mixed-noncompetitive mechanism of inhibition (E) or as individual 
Michaelis-Menten curves (F). Replots of (kcat)app and (kcat/KM)app obtained from panel F as a function of 2 are 
shown in (G) and (H), respectively. Concentrations of 2 evaluated were 0 (), 12.5 (), 25 ()/50 (), 100 
(), and 200 () µM.  
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Figure S10. Non-linear least-squares analyses of rapid reversible inhibition by manzamine E (3). Data 
acquired varying [ATP] at fixed [SA] were either fit to a global mixed-noncompetitive mechanism of 
inhibition (A) or as individual Michaelis-Menten curves (B). Replots of (kcat)app and (kcat/KM)app obtained from 
panel B as a function of 3 are shown in (C) and (D), respectively. Data acquired varying [SA] at fixed [ATP] 
were either fit to a global mixed-noncompetitive mechanism of inhibition (E) or as individual Michaelis-
Menten curves (F). Replots of (kcat)app and (kcat/KM)app obtained from panel F as a function of 3 are shown in 
(G) and (H), respectively. Concentrations of 3 evaluated were 0 (), 25 (), 50 (), 100 (), 150 (), and 
200 () µM. 
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Figure S11. Non-linear least-squares analyses of rapid reversible inhibition by manzamine F (4). Data 
acquired varying [ATP] at fixed [SA] were either fit to a global mixed-noncompetitive mechanism of 
inhibition (A) or as individual Michaelis-Menten curves (B). Replots of (kcat)app and (kcat/KM)app obtained from 
panel B as a function of 4 are shown in (C) and (D), respectively. Data acquired varying [SA] at fixed [ATP] 
were either fit to a global mixed-noncompetitive mechanism of inhibition (E) or as individual Michaelis-
Menten curves (F). Replots of (kcat)app and (kcat/KM)app obtained from panel F as a function of 4 are shown in 
(G) and (H), respectively. Concentrations of 4 evaluated were 0 (), 100 (), 150 (), 200 (), and 250 
() µM. 
 Simithy, J., et al.; Slow-binding inhibition of MtSK by manzamines; Page {PAGE  } of 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S12. Non-linear least-squares analyses of rapid reversible inhibition by deoxymanzamine X (5). 
Data acquired varying [ATP] at fixed [SA] were either fit to a global mixed-noncompetitive mechanism of 
inhibition (A) or as individual Michaelis-Menten curves (B). Replots of (kcat)app and (kcat/KM)app obtained from 
panel B as a function of 5 are shown in (C) and (D), respectively. Data acquired varying [SA] at fixed [ATP] 
were either fit to a global mixed-noncompetitive mechanism of inhibition (E) or as individual Michaelis-
Menten curves (F). Replots of (kcat)app and (kcat/KM)app obtained from panel F as a function of 5 are shown in 
(G) and (H), respectively. Concentrations of 5 evaluated were 0 (), 25 (), 50 (), 100 (), and 200 () 
µM. 
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Figure S13. Modeled effect of an inhibitor with compound 6 parameters on the activity of an MtSK-
like enzyme in steady-state inhibition assays. The model was constructed according to Fig. 2. For the 
inhibitor, the initial encounter KD’s were modeled after KI’s from Tables 1 and 2: 2 µM (free E), 8 µM (each 
binary complex E-ATP and E-SA), and 32 µM (ternary E-ATP-SA complex). To observe the maximum 
possible interference of time-dependent inhibition, the slow transition to EI* complexes was presumed to be 
possible from any enzyme inhibitor complex. The red line corresponds to modeled activity where k5 is 0.015 
s-1 (i.e., 0.91 min-1) and k6 is 0.00067 s-1 (i.e., 0.04 min-1; see Table 3). The blue line corresponds to modeled 
activity where k5 = 0 (i.e., there is no time-dependent inhibition). Activity is modeled with 5 mM SA and 1.2 
mM ATP. For reference, actual inhibition data obtained with compound 6 under identical conditions are 
shown.  
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Kinetic modeling for jump-dilution experiments 
 
The recoveries of MtSK activity following jump-dilution of preformed manzamine-MtSK complexes 
were broadly consistent with the superior properties of 6 as an inhibitor (i.e., low KI’s, high k5, and low k6) 
relative to 1 – 5. However, the post-dilution acceleration of activity typical of reversible, slow-onset 
inhibitors was not observed for 1 – 5 (see Fig. 6). To evaluate the set up of our jump-dilution experiments as 
well as garner some insight into this apparent inconsistency, we used KinTek Explorer software construct 
simplified kinetic models and evaluate broad features of anticipated results.3 It should be emphasized that 
these are not intended to be global analyses of comprehensive kinetic models. As yet, there are still many 
unknowns that preclude the effective application of such methods.  
 
Based on a two-step model for formation of an EI* complex (Fig. S14B) as well as values for KI 
(Table 1), k5, and k6 (Table 3) we evaluated the extent to which an EI* complex would be expected to 
accumulate during a one-hour preincubation between 20 µM MtSK and 1 mM inhibitor.  As shown for 1 
(Fig. S14A) and calculated for 2, 3, and 6, rapid-equilibrium formation of EI is followed by the k5/k6-
dominated transition to EI* over the course or preincubation such that in each case the dominant species at 
the conclusion of preincubation was anticipated to be EI* (Table S2). Supposing a simplified enzyme 
mechanism (i.e., one S, one ES complex) including mixed noncompetitive inhibition and the conversion of 
EI to EI* (Fig. S15A), we estimated the change in distribution of enzyme states following 1:100 dilution into 
a reaction containing a saturating concentration of substrate.  For 1 (Fig. S15B) as well as 2, 3, and 6 (Table 
S3), we supposed the rapid-equilibrium conversion of EI to E, essentially, at the time of dilution. Over the 
course of the assay, active enzyme species would then be expected to accumulate at the expense of EI*. 
Using the fraction of active enzyme species as a basis for estimation, an increase in activity ranging from 2.7 
to 5.4 fold was calculated (Table S3). Of course, an increase in activity following dilution was not observed 
for 1 – 5 (see Fig. 6).  We explored the possibility that product accumulation may interfere with an expected 
acceleration of activity in a jump-dilution experiment like ours. Including the conversion of E + P to ES in 
the mechanism markedly changed the results one would expect; similar to what we observed with 1 – 5 (Fig. 
6), an acceleration of product generation was no longer evident (e.g., with 1, Fig. S16) and more closely 
resembled our experimental results (Fig. S16C). Also consistent with our experimental observations, an 
inhibitor with the properties of 6 would still show a delay in the recovery of activity (Fig. S16D).   
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Figure S14. Preincubation association of MtSK with 1 (A) from free enzyme (E) to initial rapid-
equilibrium complex (EI) to the slow-onset complex (EI*) (B). The reaction conditions matched those of 
the preincubation in our jump-dilution experiments (i.e., 20 µM MtSK and 1 mM inhibitor). The parameters 
were as follows: KI = 120 µM (Table 1), k5 = 0.003 s-1 (i.e., 0.18 min-1) and k6 = 0.0013 s-1 (i.e., 0.08 min-1) 
(Table 3). 
 
 
  
Table S2. Relative concentrations of enzyme states at the end of preincubation 
                                Fractiona 
Inhibitor [E] [EI] [EI*] 
1 0.036 0.296 0.668 
2 0.002 0.159 0.839 
3 0.008 0.127 0.864 
6 < 0.001 0.042 0.958 
aFraction of the 20 µM total MtSK in the indicated state following 1 hr preincubation. 
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Figure S15. Predicted post-dilution recovery of MtSK following preincubation with 1. The enzyme 
model (A) was simplified to a single substrate, single product, single ES complex system and allowed for 
mixed noncompetitive inhibition in the rapid equilibrium phase. Following a nearly instantaneous conversion 
of EI to E upon dilution (compare E at t = 3600 s in the left panel of Figure S14 to E at t = 3.6 s here), slow 
accumulation of E is observed consistent with the loss of EI*. Consistent with the post-dilution conditions of 
our jump-dilution experiments, the sum of all MtSK species is 0.2 µM. E represents all active forms of 
enzyme (E and ES), and EI represents the sum of EI and ESI complexes. Parameters/constants were as 
follows: KS = 0.5 mM, KI = 0.120 mM (from Table 1), α = 1.75 (γKI/KI from Table 1), k5 = 0.003 s-1 (0.18 
min-1 from Table 3), k6 = 0.0015 s-1 (0.08 min-1 from Table 3), kf = 16.7 s-1, and kr = 0.6 s-1. 
 
 
 
 
Table S3. Calculated activity recovery following dilution. 
 Fractiona of Active Enzyme 
Inhibitor Initialb Finalc Fold Increase 
1 0.35 0.94 2.7 
2 0.14 0.60 4.3 
3 0.13 0.55 4.2 
6 0.019 0.11 5.8 
aFraction of the 0.2 µM total MtSK not bound to I (e.g., E, ES, etc.) 
bImmediately (i.e., 3.6 s) following dilution 
c1 hour following dilution (i.e., at the conclusion of the assay) 
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Figure S16. Anticipated activity recovery in a jump-dilution experiment where there is no product 
interference or product contributes to a back reaction. For panels A and B, inhibitor parameters, 
preincubation conditions, and dilution conditions were modeled after 1 (identical to Fig. S15). For panel A, kr 
= 0, and for panel B, kr = 0.6 s-1. Modeled versus observed activity recovery in jump-dilution experiments for 
manzamine A (1) (C) and cyclohexamidomanzamine A (6) (D). Parameters for modeling activity recovery 
for 1 and 6 were identical to Fig. S15, except that for 6, KI = 3.2 µM, α = 2.5, k5 = 0.0158 s-1, and k6 = 
0.00033 s-1. 
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